慢性肝病患者接种新型冠状病毒疫苗相关研究进展
Research Progress of COVID-19 Vaccination in Patients with Chronic Liver Diseases
DOI: 10.12677/ACM.2023.1361268, PDF,   
作者: 张必琼：重庆医科大学附属第二医院感染科，重庆；任 红*：重庆医科大学附属第二医院肝病研究所，重庆
关键词: 新型冠状病毒肺炎；新型冠状病毒疫苗；慢性肝病；肝损伤；COVID-19； SARS-CoV-2 Vaccine； Chronic Liver Diseases； Liver Injury
摘要: 新型冠状病毒肺炎(Coronavirus Disease 2019, COVID-19)由于其高传播率及人群普遍易感性成为威胁生命的全球健康负担。全国广泛推行新型冠状病毒疫苗接种以产生群体免疫。我国现存超3亿的慢性肝病患者，有研究表明，慢性肝病患者较健康人群对COVID-19有更高的易感性，且慢性肝病患者感染COVID-19后的重症率和死亡率升高，接种新冠疫苗可以有效降低新冠感染后的重症率和死亡率。目前有部分关于这一特殊人群接种新冠疫苗的安全性和有效性研究。本综述叙述了慢性肝病与COVID-19之间的关系，也叙述了新冠肺炎疫苗在慢性肝病这一特殊人群中的安全性和有效性。
Abstract: Coronavirus Disease 2019 (COVID-19) has become a life-threatening global health burden due to its rapid transmission rate and general susceptibility. Vaccination against SARS-Cov-2 was actively promoted worldwide. There are more than 300 million patients with chronic liver diseases in China. Patients with chronic liver diseases have a higher susceptibility to COVID-19 than healthy people. They are considered to be at a high risk for severe COVID-19 and death. SARS-Cov-2 vaccination can reduce the disease severity and mortality effectively. There are some studies on the safety and effi-cacy of COVID-19 vaccination in patients with chronic liver diseases. This review focuses on the role of COVID-19 in chronic liver diseases and the safety and efficacy of COVID-19 vaccination in this spe-cial population.
文章引用：张必琼, 任红. 慢性肝病患者接种新型冠状病毒疫苗相关研究进展[J]. 临床医学进展, 2023, 13(6): 9060-9066. https://doi.org/10.12677/ACM.2023.1361268

参考文献

[1] Whittaker, C., Walker, P., Alhaffar, M., et al. (2021) Under-Reporting of Deaths Limits Our Understanding of True Burden of COVID-19. BMJ, 375, Article No. n2239. [Google Scholar] [CrossRef] [PubMed]
[2] Biswas, M., Raham-an, S., Biswas, T.K., et al. (2020) Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology, 1-12.
[3] Mukherjee, A., Kumar, G., Turuk, A., et al. (2023) Vaccination Saves Lives: A Real-Time Study of Patients with Chronic Diseases and Severe COVID-19 Infection. QJM: An International Journal of Medicine, 116, 47-56. [Google Scholar] [CrossRef] [PubMed]
[4] Cichoż-Lach, H. and Michalak, A. (2021) Liver Injury in the Era of COVID-19. World Journal of Gastroenterology, 27, 377-390. [Google Scholar] [CrossRef] [PubMed]
[5] Alqahtani, S.A., Aljumah, A.A., Hashim, A., et al. (2020) Principles of Care for Patients with Liver Disease during the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. Annals of Saudi Medicine, 40, 273-280. [Google Scholar] [CrossRef] [PubMed]
[6] Boettler, T., Marjot, T., Newsome, P.N., et al. (2020) Impact of COVID-19 on the Care of Patients with Liver Disease: EASL-ESCMID Position Paper after 6 Months of the Pandemic. JHEP Reports, 2, Article ID: 100169. [Google Scholar] [CrossRef] [PubMed]
[7] Singh, S. and Khan, A. (2020) Clinical Characteristics and Out-comes of Coronavirus Disease 2019 among Patients with Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 159, 768-771. [Google Scholar] [CrossRef] [PubMed]
[8] Nagarajan, R., Krishnamoorthy, Y., Rajaa, S. and Hariharan, V.S. (2022) COVID-19 Severity and Mortality among Chronic Liver Disease Patients: A Systematic Review and Me-ta-Analysis. Preventing Chronic Disease, 19, E53. [Google Scholar] [CrossRef] [PubMed]
[9] Steele, M.K., Couture, A., Reed, C., et al. (2022) Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Network Open, 5, e2220385. [Google Scholar] [CrossRef] [PubMed]
[10] Tulimilli, S.V., Dallavalasa, S., Basavaraju, C.G., et al. (2022) Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vac-cines, 10, Article No. 1751. [Google Scholar] [CrossRef] [PubMed]
[11] Ioannou, G.N., Liang, P.S., Locke, E., et al. (2021) Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventila-tion, and Mortality. Hepatology, 74, 322-335. [Google Scholar] [CrossRef] [PubMed]
[12] Kim, D., Adeniji, N., Latt, N., et al. (2021) Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-Center Study. Clinical Gastroenterology and Hepatology, 19, 1469-1479. [Google Scholar] [CrossRef] [PubMed]
[13] Moon, A.M., Webb, G.J., Aloman, C., et al. (2020) High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-Existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry. Journal of Hepatology, 73, 705-708. [Google Scholar] [CrossRef] [PubMed]
[14] Marjot, T., Moon, A.M., Cook, J.A., et al. (2021) Outcomes Fol-lowing SARS-CoV-2 Infection in Patients with Chronic Liver Disease: An International Registry Study. Journal of Hepatology, 74, 567-577. [Google Scholar] [CrossRef] [PubMed]
[15] Sagnelli, C., Montella, L., Grimaldi, P., et al. (2022) COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens, 11, Article No. 816. [Google Scholar] [CrossRef] [PubMed]
[16] Yu, Y., Li, X. and Wan, T. (2023) Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis. Digestive Diseases and Sciences, 68, 1615-1631. [Google Scholar] [CrossRef] [PubMed]
[17] Marjot, T., Buescher, G., Sebode, M., et al. (2021) SARS-CoV-2 Infection in Patients with Autoimmune Hepatitis. Journal of Hepatology, 74, 1335-1343. [Google Scholar] [CrossRef] [PubMed]
[18] Chavez-Tapia, N.C., Torre-Delgadillo, A., Tellez-Avila, F.I. and Uribe, M. (2007) The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis. Current Medicinal Chemistry, 14, 2954-2958. [Google Scholar] [CrossRef] [PubMed]
[19] Sharma P., Kumar A., Anikhindi S., et al. (2021) Effect of COVID-19 on Pre-Existing Liver Disease: What Hepatologist Should Know? Journal of Clinical and Experimental Hepatology, 11, 484-493. [Google Scholar] [CrossRef] [PubMed]
[20] Premkumar, M. and Kedarisetty, C.K. (2021) Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. Journal of Clinical and Translational Hepatology, 9, 256-264. [Google Scholar] [CrossRef] 
[21] Khandker, S.S., Godman, B., Jawad, M.I., et al. (2021) A Sys-tematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 9, Article No. 1387. [Google Scholar] [CrossRef] [PubMed]
[22] Amodio, E., Minutolo, G., Casuccio, A., et al. (2022) Adverse Reac-tions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System. Vaccines, 10, Article No. 345. [Google Scholar] [CrossRef] [PubMed]
[23] Xia, S., Zhang, Y., Wang, Y., et al. (2021) Safety and Immuno-genicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial. The Lancet Infectious Diseases, 21, 39-51. [Google Scholar] [CrossRef] 
[24] Novak, N., Tordesillas, L. and Cabanillas, B. (2022) Adverse Rare Events to Vaccines for COVID-19: From Hypersensitivity Reactions to Thrombosis and Thrombocytopenia. Inter-national Reviews of Immunology, 41, 438-447. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, Y., Xu, Z., Wang, P., et al. (2022) New-Onset Auto-immune Phenomena Post-COVID-19 Vaccination. Immunology, 165, 386-401. [Google Scholar] [CrossRef] [PubMed]
[26] Wong, C.K.H., Mak, L.Y., Au, I., et al. (2022) Risk of Acute Liver Injury Following the mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccines. Journal of Hepatology, 77, 1339-1348. [Google Scholar] [CrossRef] [PubMed]
[27] Vojdani, A. and Kharrazian, D. (2020) Potential Antigenic Cross-Reactivity between SARS-CoV-2 and Human Tissue with a Possible Link to an Increase in Autoimmune Diseases. Clinical Immunology, 217, Article ID: 108480. [Google Scholar] [CrossRef] [PubMed]
[28] Roy, A., Verma, N., Singh, S., et al. (2022) Immune-Mediated Liver Injury Following COVID-19 Vaccination: A Systematic Review. Hepatology Communications, 6, 2513-2522. [Google Scholar] [CrossRef] [PubMed]
[29] Cao, Z., Gui, H., Sheng, Z., Xin, H. and Xie, Q. (2022) Letter to the Editor: Exacerbation of Autoimmune Hepatitis after COVID-19 Vaccination. Hepatology, 75, 757-759. [Google Scholar] [CrossRef] [PubMed]
[30] Luo, D., Chen, X., Du, J., et al. (2023) Immunogenicity of COVID-19 Vaccines in Chronic Liver Disease Patients and Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Liver International, 43, 34-48. [Google Scholar] [CrossRef] [PubMed]
[31] Thuluvath, P.J., Robarts, P. and Chauhan, M. (2021) Analysis of Antibody Responses after COVID-19 Vaccination in Liver Transplant Recipients and Those with Chronic Liver Diseases. Journal of Hepatology, 75, 1434-1439. [Google Scholar] [CrossRef] [PubMed]
[32] Willuweit, K., Frey, A., Passenberg, M., et al. (2022) Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of An-tibody Titers. Vaccines, 10, Article No. 377. [Google Scholar] [CrossRef] [PubMed]
[33] Ruether, D.F., Schaub, G.M., Duengelhoef, P.M., et al. (2022) SARS-CoV2-Specific Humoral and T-Cell Immune Response after Second Vaccination in Liver Cirrhosis and Trans-plant Patients. Clinical Gastroenterology and Hepatology, 20, 162-172. [Google Scholar] [CrossRef] [PubMed]
[34] Doi, H., Iyer, T.K., Carpenter, E., et al. (2012) Dysfunctional B-Cell Activation in Cirrhosis Resulting from Hepatitis C Infection Associated with Disappearance of CD27-Positive B-Cell Population. Hepatology, 55, 709-719. [Google Scholar] [CrossRef] [PubMed]
[35] John, B.V., Sidney, B.A.T., Moon, A., et al. (2022) Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastro-enterology and Hepatology, 20, 2405-2408. [Google Scholar] [CrossRef] [PubMed]
[36] John, B.V., Deng, Y., Schwartz, K.B., et al. (2022) Postvaccination COVID-19 Infection Is Associated with Reduced Mortality in Patients with Cirrhosis. Hepatology, 76, 126-138. [Google Scholar] [CrossRef] [PubMed]
[37] Cao, Z., Zhang, C., Zhao, S., et al. (2022) COVID-19 Vaccines in Patients with Decompensated Cirrhosis: A Retrospective Cohort on Safety Data and Risk Factors Associated with Unvaccinated Status. Infectious Diseases of Poverty, 11, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[38] Bakasis, A.-D., Bitzogli, K., Mouziouras, D., et al. (2022) Anti-body Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses, 14, Article No. 207. [Google Scholar] [CrossRef] [PubMed]
[39] Davidov, Y., Tsaraf, K., Cohen-Ezra, O., et al. (2022) Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine among Liver Transplantation Recipients. Liver Transplantation, 28, 215-223. [Google Scholar] [CrossRef] [PubMed]
[40] D’Offizi. G., Agrati. C., Visco-Comandini. U., et al. (2022) Coordinated Cellular and Humoral Immune Responses after Two-Dose SARS-CoV2 mRNA Vaccination in Liver Transplant Recipi-ents. Liver International, 42, 180-186. [Google Scholar] [CrossRef] [PubMed]
[41] Rabinowich, L., Grupper, A., Baruch, R., et al. (2021) Low Immunogenicity to SARS-CoV-2 Vaccination among Liver Transplant Recipients. Journal of Hepatology, 75, 435-438. [Google Scholar] [CrossRef] [PubMed]
[42] Sakai, A., Morishita, T. and Matsunami, H. (2022) Antibody Re-sponse after a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients. Transplant International, 35, Article ID: 10321. [Google Scholar] [CrossRef] [PubMed]
[43] Timmermann, L., Globke, B., Lurje, G., et al. (2021) Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 9, Article No. 1422. [Google Scholar] [CrossRef] [PubMed]
[44] Fix, O.K., Blumberg, E.A., Chang, K.M., et al. (2021) American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Dis-ease 2019 Infection in Patients with Liver Disease. Hepatology, 74, 1049-1064. [Google Scholar] [CrossRef] [PubMed]
[45] Kamar, N., Abravanel, F., Marion, O., et al. (2021) Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 385, 661-662. [Google Scholar] [CrossRef] 
[46] Oosting, S.F., van der Veldt, A., Fehrmann, R., et al. (2022) Immu-nogenicity after Second and Third mRNA-1273 Vaccination Doses in Patients Receiving Chemotherapy, Immunotherapy, or Both for Solid Tumours. The Lancet Oncology, 23, 833-835. [Google Scholar] [CrossRef] 
[47] Peeters, M., Verbruggen, L., Teuwen, L., et al. (2021) Re-duced Humoral Immune Response after BNT162b2 Coronavirus Disease 2019 Messenger RNA Vaccination in Cancer Patients under Antineoplastic Treatment. ESMO Open, 6, Article ID: 100274. [Google Scholar] [CrossRef] [PubMed]
[48] Levin, E.G., Lustig, Y., Cohen, C., et al. (2021) Waning Im-mune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 385, e84. [Google Scholar] [CrossRef] 
[49] He, T., Zhou, Y., Xu, P., et al. (2022) Safety and Antibody Re-sponse to Inactivated COVID-19 Vaccine in Patients with Chronic Hepatitis B Virus Infection. Liver International, 42, 1287-1296. [Google Scholar] [CrossRef] [PubMed]
[50] Xiang, T., Liang, B., Wang, H., et al. (2021) Safety and Immu-nogenicity of a SARS-CoV-2 Inactivated Vaccine in Patients with Chronic Hepatitis B Virus Infection. Cellular & Mo-lecular Immunology, 18, 2679-2681. [Google Scholar] [CrossRef] [PubMed]
[51] Wang, J., Hou, Z., Liu, J., et al. (2021) Safety and Immunogen-icity of COVID-19 Vaccination in Patients with Non-Alcoholic Fatty Liver Disease (CHESS2101): A Multicenter Study. Journal of Hepatology, 75, 439-441. [Google Scholar] [CrossRef] [PubMed]
[52] Hegyi, P.J., Vancsa, S., Ocskay, K., et al. (2021) Metabolic Asso-ciated Fatty Liver Disease Is Associated with an Increased Risk of Severe COVID-19: A Systematic Review with Me-ta-Analysis. Frontiers in Medicine, 8, Article 626425. [Google Scholar] [CrossRef] [PubMed]
[53] Pan, L., Huang, P., Xie, X., et al. (2021) Metabolic Associated Fatty Liver Disease Increases the Severity of COVID-19: A Meta-Analysis. Digestive and Liver Disease, 53, 153-157. [Google Scholar] [CrossRef] [PubMed]
[54] Singh, A., Hussain, S. and Antony, B. (2021) Non-Alcoholic Fatty Liver Disease and Clinical Outcomes in Patients with COVID-19: A Comprehensive Systematic Review and Me-ta-Analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 813-822. [Google Scholar] [CrossRef] [PubMed]
[55] Duengelhoef, P., Hartl, J., Ruther, D., et al. (2022) SARS-CoV-2 Vaccination Response in Patients with Autoimmune Hepatitis and Autoimmune Cholestatic Liver Disease. United Euro-pean Gastroenterology Journal, 10, 319-329. [Google Scholar] [CrossRef] [PubMed]
[56] Schneider, L., Schubert, L., Winkler, F., et al. (2022) SARS-CoV-2 Vac-cine Response in Patients with Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 20, 2145-2147. [Google Scholar] [CrossRef] [PubMed]
[57] Li, H., Wang, Y., Ao, L., et al. (2022) Association between Immu-nosuppressants and Poor Antibody Responses to SARS-CoV-2 Vaccines in Patients with Autoimmune Liver Diseases. Frontiers in Immunology, 13, Article 988004. [Google Scholar] [CrossRef] [PubMed]

为你推荐